300 related articles for article (PubMed ID: 2896139)
1. Comparison of delayed-release 5-aminosalicylic acid (mesalazine) and sulfasalazine as maintenance treatment for patients with ulcerative colitis.
Riley SA; Mani V; Goodman MJ; Herd ME; Dutt S; Turnberg LA
Gastroenterology; 1988 Jun; 94(6):1383-9. PubMed ID: 2896139
[TBL] [Abstract][Full Text] [Related]
2. Comparison of delayed release 5 aminosalicylic acid (mesalazine) and sulphasalazine in the treatment of mild to moderate ulcerative colitis relapse.
Riley SA; Mani V; Goodman MJ; Herd ME; Dutt S; Turnberg LA
Gut; 1988 May; 29(5):669-74. PubMed ID: 2899536
[TBL] [Abstract][Full Text] [Related]
3. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial.
Rachmilewitz D
BMJ; 1989 Jan; 298(6666):82-6. PubMed ID: 2563951
[TBL] [Abstract][Full Text] [Related]
4. Role of mesalazine in acute and long-term treatment of ulcerative colitis and its complications.
Schroeder KW
Scand J Gastroenterol Suppl; 2002; (236):42-7. PubMed ID: 12408503
[TBL] [Abstract][Full Text] [Related]
5. Coated oral 5-aminosalicylic acid (Claversal) is equivalent to sulfasalazine for remission maintenance in ulcerative colitis. A double-blind study.
Ardizzone S; Petrillo M; Molteni P; Desideri S; Bianchi Porro G
J Clin Gastroenterol; 1995 Dec; 21(4):287-9. PubMed ID: 8583101
[TBL] [Abstract][Full Text] [Related]
6. Adverse effects of sulfasalazine and treatment of ulcerative colitis with mesalazine.
Nakajima H; Munakata A; Yoshida Y
J Gastroenterol; 1995 Nov; 30 Suppl 8():115-7. PubMed ID: 8563870
[TBL] [Abstract][Full Text] [Related]
7. Oral delayed-release mesalazine: a review of its use in ulcerative colitis and Crohn's disease.
Prakash A; Markham A
Drugs; 1999 Mar; 57(3):383-408. PubMed ID: 10193690
[TBL] [Abstract][Full Text] [Related]
8. Double-blind comparative study of sulfasalazine and controlled-release mesalazine tablets in the treatment of active ulcerative colitis.
Munakata A; Yoshida Y; Muto T; Tsuchiya S; Fukushima T; Hiwatashi N; Kobayashi K; Kitano A; Shimoyama T; Inoue M
J Gastroenterol; 1995 Nov; 30 Suppl 8():108-11. PubMed ID: 8563868
[TBL] [Abstract][Full Text] [Related]
9. An oral preparation of mesalamine as long-term maintenance therapy for ulcerative colitis. A randomized, placebo-controlled trial. The Mesalamine Study Group.
Ann Intern Med; 1996 Jan; 124(2):204-11. PubMed ID: 8533995
[TBL] [Abstract][Full Text] [Related]
10. A comparison of mesalamine suspension enema and oral sulfasalazine for treatment of active distal ulcerative colitis in adults.
Kam L; Cohen H; Dooley C; Rubin P; Orchard J
Am J Gastroenterol; 1996 Jul; 91(7):1338-42. PubMed ID: 8677990
[TBL] [Abstract][Full Text] [Related]
11. Treatment of ulcerative colitis with oral 5-aminosalicylic acid including patients with adverse reactions to sulfasalazine.
Habal FM; Greenberg GR
Am J Gastroenterol; 1988 Jan; 83(1):15-9. PubMed ID: 2892391
[TBL] [Abstract][Full Text] [Related]
12. Is maintenance therapy always necessary for patients with ulcerative colitis in remission?
Ardizzone S; Petrillo M; Imbesi V; Cerutti R; Bollani S; Bianchi Porro G
Aliment Pharmacol Ther; 1999 Mar; 13(3):373-9. PubMed ID: 10102971
[TBL] [Abstract][Full Text] [Related]
13. Intermittent therapy with high-dose 5-aminosalicylic acid enemas for maintaining remission in ulcerative proctosigmoiditis.
d'Albasio G; Trallori G; Ghetti A; Milla M; Nucci A; Pacini F; Morettini A
Dis Colon Rectum; 1990 May; 33(5):394-7. PubMed ID: 1970284
[TBL] [Abstract][Full Text] [Related]
14. A double-blind comparison of balsalazide, 6.75 g, and sulfasalazine, 3 g, as sole therapy in the management of ulcerative colitis.
Mansfield JC; Giaffer MH; Cann PA; McKenna D; Thornton PC; Holdsworth CD
Aliment Pharmacol Ther; 2002 Jan; 16(1):69-77. PubMed ID: 11856080
[TBL] [Abstract][Full Text] [Related]
15. Systemic uptake of 5-aminosalicylic acid from olsalazine and eudragit L coated mesalazine in patients with ulcerative colitis in remission.
Ewe K; Becker K; Ueberschaer B
Z Gastroenterol; 1996 Apr; 34(4):225-9. PubMed ID: 8686349
[TBL] [Abstract][Full Text] [Related]
16. Effects of mesalazine substitution on salicylazosulfapyridine-induced seminal abnormalities in men with ulcerative colitis.
Kjaergaard N; Christensen LA; Lauritsen JG; Rasmussen SN; Hansen SH
Scand J Gastroenterol; 1989 Sep; 24(7):891-6. PubMed ID: 2572047
[TBL] [Abstract][Full Text] [Related]
17. Double-blind comparison of slow-release 5-aminosalicylate and sulfasalazine in remission maintenance in ulcerative colitis.
Mulder CJ; Tytgat GN; Weterman IT; Dekker W; Blok P; Schrijver M; van der Heide H
Gastroenterology; 1988 Dec; 95(6):1449-53. PubMed ID: 2903110
[TBL] [Abstract][Full Text] [Related]
18. Balsalazide: a review of its therapeutic use in mild-to-moderate ulcerative colitis.
Muijsers RB; Goa KL
Drugs; 2002; 62(11):1689-705. PubMed ID: 12109930
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the efficacy and safety of 1.5 compared with 3.0 g oral slow-release mesalazine (Pentasa) in the maintenance treatment of ulcerative colitis. Dutch Pentasa Study Group.
Fockens P; Mulder CJ; Tytgat GN; Blok P; Ferwerda J; Meuwissen SG; Tuynman HA; Dekker W; Gasthuis K; van Hees PA
Eur J Gastroenterol Hepatol; 1995 Nov; 7(11):1025-30. PubMed ID: 8680900
[TBL] [Abstract][Full Text] [Related]
20. Prolonged-release mesalazine: a review of its therapeutic potential in ulcerative colitis and Crohn's disease.
Clemett D; Markham A
Drugs; 2000 Apr; 59(4):929-56. PubMed ID: 10804042
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
